TL;DR
This commentary critically examines a study on inflammatory markers and colorectal cancer (CRC), highlighting potential issues with statistical rigor and control group selection. The authors suggest that while the study offers exploratory value, future research should employ more robust methodologies to confirm findings and advance these markers towards clinical application.
What Problem Does This Paper Address?
The original study by Zhou et al. aimed to systematically evaluate the associations between 12 composite inflammatory indices and colorectal cancer (CRC) risk and mortality using NHANES data. This commentary, however, addresses the methodological soundness of that original study. Specifically, it questions whether the study's approach adequately accounts for potential biases and limitations inherent in its design, which could impact the reliability of its conclusions regarding the utility of inflammatory biomarkers for CRC risk stratification. The core problem addressed by this commentary is ensuring that research in this area is methodologically rigorous enough to lead to trustworthy clinical applications.
Methods
This commentary does not introduce new methods but rather critiques the methods used in the original study. The authors point out that the original study mitigated the issue of multiple comparisons through multi-model adjustments but did not employ rigorous statistical correction methods like Bonferroni or false discovery rate. They also discuss the definition of the control group, which included individuals with other inflammatory diseases or cancers, potentially introducing confounding. Finally, they raise concerns about the cross-sectional design and the timing of inflammatory marker measurements (after cancer diagnosis), which makes it difficult to establish causality.
Datasets
The commentary refers to the NHANES (National Health and Nutrition Examination Survey) data used in the original study. No new datasets were introduced or created for this commentary.
Key Insights and Ideas
- Multiple Comparisons Risk: The original study's approach to multiple comparisons, while attempting to mitigate its impact, may still leave it vulnerable to false positives due to the lack of stringent statistical corrections.
- Control Group Definition: Defining the control group as all non-CRC participants is problematic because it includes individuals with other inflammatory conditions or cancers, which can confound the results and dilute the true association with CRC.
- Causality vs. Consequence: The cross-sectional design and the measurement of inflammatory markers after cancer diagnosis make it challenging to determine if these markers are causes of CRC or consequences of the disease and its treatment. This uncertainty limits their direct use as early screening biomarkers.
Key Results
This commentary does not present quantitative results. Instead, it offers qualitative critiques of the original study's methodology and interpretation. The "results" are the identified methodological concerns and suggestions for improvement.
Limitations and Future Work
The authors of this commentary highlight several limitations in the original study:
- Statistical Rigor: The lack of explicit multiple comparison corrections (e.g., Bonferroni, false discovery rate) increases the risk of false positives.
- Control Group Specificity: The broad definition of the control group may lead to confounding and underestimation of effect sizes.
- Causality Ambiguity: The cross-sectional design and post-diagnosis measurement of markers hinder the establishment of a causal link between inflammatory markers and CRC development.
They suggest future work should:
- Employ Prospective Designs: To better establish causality and temporal relationships.
- Refine Control Groups: By excluding individuals with other inflammatory diseases or cancers, or by using propensity score matching.
- Conduct Clinical Utility Assessments: To rigorously evaluate the practical application of these biomarkers.
- Explicitly Address Limitations: Future studies should clearly state limitations related to multiple comparisons and control group selection.
Ultimately, the authors advocate for more robust methodologies to advance these inflammatory biomarkers toward translational application and higher-level evidence for CRC management.
Summary updated